Pharmacy contractors reminded to complete CPAF screening process by 31 August


Share post:

The Pharmaceutical Services Negotiating Committee (PSNC) has been reminding contractors to complete the 2022/23 Community Pharmacy Assurance Framework (CPAF) screening questionnaire by midnight on Wednesday, 31 August 2022.

As a result of NHS regulations introduced at the end of 2020, completion of CPAF is now a requirement of the Terms of Service. “Therefore, contractors must complete the screening questionnaire and, if required, the full CPAF questionnaire,” said PSNC.

It has also recommended that any contractor who has yet to do so takes immediate action. “It should only take approximately 10-20 minutes to complete.”

Information and instructions on how to complete the screening questionnaire has been shared either via an email from the NHS Business Services Authority (NHSBSA) or from their own Head Office.

Contractors are advised to contact NHSBSA by emailing [email protected] if they have not received details of the questionnaire, or if they have any problems or queries completing the questionnaire.

PSNC has also published PSNC Briefing 017/22: CPAF screening process for 2022/23, which provides guidance for contractors on the CPAF screening process and also includes the screening questions for 2022/23.


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

Shadow Health Minister Preet Kaur Gill visits pharmacy in Staffordshire

Preet Kaur Gill, Shadow Minister for Primary Care and Public Health, has paid a recent visit to a...

Superdrug to halt single-use vape sales in UK, Ireland due to environmental concerns

British pharmacy chain Superdrug has announced plans to cease the sale of disposable vapes in all its UK...

Closure of temporary registers by 31 March 2024: GPhC

Pharmacists on the temporary register will be automatically removed on April 1, unless they have applied to rejoin the...

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...